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The NAD+-dependent protein deacetylase SIRT1
regulates energy metabolism, responses to stress,
and aging by deacetylating many different proteins,
including histones and transcription factors. The
mechanisms controlling SIRT1 enzymatic activity
are complex and incompletely characterized, yet
essential for understanding how to develop thera-
peutics that target SIRT1. Here, we demonstrate
that the N-terminal domain of SIRT1 (NTERM) can
trans-activate deacetylation activity by physically in-
teracting with endogenous SIRT1 and promoting its
association with the deacetylation substrate NF-kB
p65. Twomotifswithin theNTERMdomain contribute
to activation of SIRT1-dependent activities, and ex-
pression of one of these motifs in mice is sufficient
to lower fasting glucose levels and improve glucose
tolerance in a manner similar to overexpression of
SIRT1. Our results provide insights into the regulation
of SIRT1 activity and a rationale for pharmacological
control of SIRT1-dependent activities.
INTRODUCTION
The NAD+-dependent deacetylase SIRT1 is a modifier of tran-
scriptional outputs that regulate lipid and glucose metabolism,
inflammatory signaling, and programmed cell death through its
effects on chromatin structure and transcription factor activity
(Haigis and Sinclair, 2010; Satoh et al., 2011; Sinclair and
Guarente, 2014). Increased SIRT1 activity enhances mitochon-
drial biogenesis, suppresses inflammation, prevents apoptosis
following DNA damage, and generally promotes cell survival in
degenerative conditions (Banks et al., 2008; Chen et al., 2005;
Jiang et al., 2012; Kang et al., 2009; Kim et al., 2007a; Pfluger
et al., 2008; Yuan et al., 2011). The deacetylase activity of
SIRT1 is limited by cellular levels of NAD+, which fluctuate in
response to changing rates of NAD+ biosynthesis and consump-Celltion (Houtkooper et al., 2010; Nakahata et al., 2009; Ramsey
et al., 2009; Revollo et al., 2004). Several protein regulators of
SIRT1 also have been identified, including the positive regulators
AROS (active regulator of SIRT1) and Necdin (Hasegawa and
Yoshikawa, 2008; Kim et al., 2008) and an inhibitory protein
DBC1 (deleted in breast cancer 1) (Kim et al., 2008; Zhao et al.,
2008). Phosphorylation of SIRT1 also can affect deacetylation
activity by regulating its interactions with protein substrates
(Back et al., 2011; Kang et al., 2009; Nasrin et al., 2009; Nin
et al., 2012; Sasaki et al., 2008). Additional posttranslational
modifications of SIRT1, including methylation, sumoylation,
and nitrosylation, have been reported (Flick and Lu¨scher, 2012;
Revollo and Li, 2013) and remain to be functionally character-
ized. Expression of SIRT1 increases following DNA damage
(Kang et al., 2009; Wang et al., 2006, 2008; Yuan et al., 2012),
and a growing list of transcription factors have been shown to in-
crease or decrease Sirt1 expression (Revollo and Li, 2013). It is
well established that SIRT1 is broadly involved with regulating
cellular metabolism and stress-dependent signaling. However,
the molecular mechanisms that govern substrate selection by
SIRT1 (Blander et al., 2005; Pan et al., 2012) and regulate its de-
acetylation activity (Canto´ and Auwerx, 2012; Sinclair and Guar-
ente, 2014) are poorly understood.
Seven mammalian paralogs of the founder protein SIR2 in
yeast, SIRT1 through SIRT7, share a conserved catalytic core
but have distinctive biological activities that are ascribed to the
nonconserved, flanking regions of each enzyme (Satoh et al.,
2011). The ESA motif (Essential for SIRT1 Deacetylase Activity;
Figure 1A), located C-terminal to the catalytic core of SIRT1, is
suggested to physically interact with the core domain to enable
deacetylase activity (Kang et al., 2011). SIRT1 also has a large,
N-terminally flanking domain that interacts with AROS (Kim
et al., 2007b), the active regulator of SIRT1, as well as small
molecule activators of deacetylase activity (Milne et al., 2007).
The numerous sites of posttranslational modification located in
the N-terminal domain of SIRT1 and its interactions with protein
and small molecule activators of deacetylase activity together
suggested this domain functions as a regulator of SIRT1-depen-
dent activities. Here, we report that overexpression of the N-ter-
minal domain of SIRT1 (Figure 1A; NTERM, residues 1–221)Reports 10, 1665–1673, March 17, 2015 ª2015 The Authors 1665
Figure 1. Expression of NTERM Activates
Endogenous SIRT1
(A) (Top) Schematic representation of SIRT1
N-terminal, catalytic core, and C-terminal do-
mains. (Bottom) Peptides spanning the NTERM
domain and including the activatingmotifs A and B
(dark brown) were expressed in cells to monitor
effects on p65 acetylation (Figure 2). A region of
predicted disorder (light brown) separates motifs
A and B. A model depicting the interaction of
NTERM motifs A and B, functioning in trans as a
dimerization interface (dimer, left side) or in cis to
stabilize the fold of the NTERM domain (monomer,
right side).
(B) Acetylation of NF-kB p65 was monitored by
western blotting whole-cell extracts from HepG2
cells co-expressing SIRT1, the NTERM domain, or
CTERM. Expression of the catalytically inactive
NTERM domain lowers acetyl-p65 to the same
level as overexpression of enzymatically active
SIRT1 (Figure S1).
(C) The levels of acetyl-p65 were quantitated for
experiments in cells transfected with 1 mg of each
plasmid including SIRT1, CTERM, NTERM, or
empty vector. The means and SEs are shown for
four experiments normalized to total NF-kB and
expressed as a percentage of the acetylated NF-
kB in control cells.
(D) NTERM overexpression decreases acetylation
of p65 NF-kB levels and this effect is antagonized
by the SIRT1 inhibitor EX-527. HepG2 cells were
transfected with NTERM (top) or SIRT1 (bottom)
and grown for 48 hr in the presence of DMSO
(2%) or EX-527 (10 or 25 mM) prior to western
blotting. NF-kB acetylation increases with
increasing concentrations of the SIRT1 inhibitor
EX-527 in HepG2 cells expressing NTERM (top)
or SIRT1 (bottom), indicating the effect of NTERM
overexpression is dependent upon SIRT1 enzy-
matic activity.
(E) Pepck expression increases significantly
in mouse primary hepatocytes expressing
NTERM, similar to the effects of SIRT1 over-
expression. The NTERM construct with the
native nuclear localization signal (NLS) behaved similarly to the NTERM-NLS construct with an additional NLS added to its N terminus. Pepck transcripts
were quantitated by qRT-PCR. The means and SEs are shown for four independent experiments.activates SIRT1-dependent activities in mammalian cells. This
trans-activation of SIRT1 function is mediated by two separate
motifs within NTERM that interact with each other and stabilize
complexes of SIRT1 with deacetylation substrates. Mice trans-
duced with an adenovirus expressing one of these NTERM
motifs showed reduced fasting glucose levels and enhanced
glucose tolerance, similar to mice overexpressing full-length
SIRT1. These findings suggest a mechanistic framework for
examining substrate selection and the regulation of SIRT1 enzy-
matic activity.
RESULTS
NTERM Expression Increases SIRT1-Dependent
Activities
We expressed the NTERMdomain of SIRT1 (Figure 1A) in HepG2
cells to examine the effects on protein acetylation and gene1666 Cell Reports 10, 1665–1673, March 17, 2015 ª2015 The Authorexpression linked to SIRT1 enzymatic activity. Acetylation of
Lys310 in the p65 subunit of NF-kB, a well-characterized target
of SIRT1 deacetylation (Ghosh et al., 2007; Yeung et al., 2004),
was monitored in cells overexpressing the NTERM domain.
Remarkably, the acetylation of p65(Lys310) decreased in res-
ponse to increasing NTERM expression (Figures 1B and 1C).
The maximal effect of NTERM expression, a 66% decrease in
p65 acetylation, is comparable to that resulting from high-level
overexpression of enzymatically active SIRT1 (Figures 1C and
S1A). In contrast to NTERM overexpression, the levels of
acetyl-p65 were unaffected by overexpression of the SIRT1
C-terminal domain (Figure 1A; CTERM, residues 509–737) that
includes the ESA motif required for enzymatic activity (Kang
et al., 2011; Figures 1C and S1B). We additionally examined
the acetylation status of the transcription factor p53, another
well-characterized substrate of SIRT1 (Hasegawa and Yoshi-
kawa, 2008; Kim et al., 2007b; Vaziri et al., 2001), and founds
Figure 2. Two Motifs within NTERM Activate
SIRT1 and Physically Interact
(A) SIRT1 is efficiently co-immunoprecipitated with
HA-tagged NTERM in HepG2 cells, andmore SIRT1
is pulled down in the complex with HA-NTERM as
SIRT1 expression is increased.
(B) Acetylation levels of NF-kB were monitored in
HepG2 cells expressing the p65 subunit of NF-kB
together with the NTERM construct (a, residues 1–
221) or one of the indicated constructs (b–k) shown
in Figure 1A. The positions of molecular weight
markers are shown at right.
(C) Two independent motifs within NTERM promote
deacetylation of NF-kB by endogenous SIRT1.
Strongly activating peptides c, e, and h (light gray)
decreased p65 acetylation to 23%–34% of the
vector control. NTERM peptides b, d, i, and k (me-
dium gray) showed intermediate levels of activity
(p65 acetylation levels 45%–62% of the control
values). Peptides f, g, and j (black) had no significant
effect on p65 acetylation levels relative to the pCMV
control. The means and SEs are shown for four
independent experiments including the represen-
tative experiment shown in (B). The results are
normalized to total NF-kB and expressed as a
percentage of the acetylated NF-kB in control cells.
(D) NTERMmotif A physically interacts with motif B.
HEK293 cells were transfected with 1 mg DNA en-
coding SIRT1(D52), SIRT1(D108), SIRT1(D163), or
SIRT1(D221) together with 2 mg DNA encoding HA-
tagged motif A (residues 1–52). The motif A peptide
co-immunoprecipitated proteins containing motif B
(SIRT1(D52) SIRT1(D108), and SIRT1(D163)), but
not the SIRT1(D221) protein lacking the NTERM
domain.that cellular levels of acetyl-p53 were coordinately decreased
with increasing NTERM expression (Figures S1C and S1D).
The cellular concentration of SIRT1 protein was unaffected by
overexpression of NTERM (Figure S1E), suggesting that NTERM
functions by increasing the enzymatic activity of endogenous
SIRT1. Consistent with this mechanism, the small molecule
SIRT1 inhibitor EX-527 antagonized the effect of NTERM and re-
turned p65 acetylation to control levels (Figure 1D). The expres-
sion of Pepck (phosphoenolpyruvate carboxykinase) mRNA was
increased by NTERM overexpression in primary hepatocytes
(Figure 1E), another hallmark of increased SIRT1 activity.
Together, these molecular readouts indicate a widespread acti-
vation of SIRT1-dependent processes (Grimm et al., 2011;
Rodgers et al., 2005) concordant with NTERM overexpression.
The Recombinant NTERM Domain Interacts with SIRT1
To examine the mechanism of this change in SIRT1-dependent
processes, we next measured the physical interactions of
SIRT1 with NTERM and deacetylation substrates. Myc-tagged
SIRT1 was efficiently co-immunoprecipitated by the HA-tagged
NTERM domain expressed in human HepG2 cells (Figure 2A),
and in the reciprocal pull-down, HA-tagged SIRT1 was co-
immunoprecipitated with Myc-tagged NTERM domain (not
shown). Increasing SIRT1 expression resulted in more SIRT1 in
complex with HA-NTERM. Deletion of the N-terminal domainCellof SIRT1 (SIRT1(D221) protein) eliminated the physical interac-
tion with recombinant NTERM domain (Figure S2A), suggesting
that the NTERM domains of both proteins either directly bind
to each other or are incorporated into a larger complex. Indeed,
two different NTERM domains tagged with Myc or HA could
be co-immunoprecipitated from HEK293 cell lysates (Fig-
ure S2B), whereas the recombinant C-terminal domain of
SIRT1 (SIRT1(509–737) protein; Figure S2A) did not interact
with NTERM. Full-length SIRT1 proteins with Myc and FLAG
tags were also efficiently co-immunoprecipitated (not shown).
Two NTERM Motifs Independently Stimulate SIRT1
Activities
The amino acid sequence of NTERM consists of two regions of
predicted a-helical character that are separated by a low-
complexity sequence indicative of disorder (Figure 1A). Intrinsi-
cally disordered regions of proteins are frequently involved in
protein-protein interactions (Me´sza´ros et al., 2011). Deletion
mutagenesis identified two regions within NTERM that could
trans-activate SIRT1 (Figure 2). A series of Myc-tagged peptides
was expressed in HepG2 cells (Figure 1A) spanning NTERM
residues 1–26 (peptide b), 1–52 (peptide c), 1–108 (peptide d),
1–163 (peptide e), 27–52 (peptide f), 52–108 (peptide g), 52–
221 (peptide h), 108–221 (peptide i), 108–163 (peptide j), and
163–221 (peptide k). Most of these constructs were abundantlyReports 10, 1665–1673, March 17, 2015 ª2015 The Authors 1667
expressed, although we could not verify the expression of short
peptides b and f by western blot analysis (Figure 2B). A pattern
emerged in which peptides from two different regions of NTERM
significantly decreased the acetylation of p65 NFkB (Figures 2B
and 2C). Strongly activating peptides (c, e, and h) decreased p65
acetylation to 23%–34% of that seen in cells transfected with
vector only. Peptides b, d, i, and k showed intermediate levels
of activity, decreasing p65 acetylation levels to 45%–62% of
control values, whereas constructs f, g, and j had no significant
effect on p65 acetylation. The results suggest that NTERM resi-
dues 1–52 (motif A; Figure 1A) and 163–221 (motif B) comprise
independent motifs that when overexpressed can trans-activate
SIRT1-dependent cellular activities (Figure 2C). Notably, these
motifs correspond to the regions of NTERM that are predicted
to be a-helical. Motif B overlaps with a region that is essential
for activation of SIRT1 enzymatic activity by small molecule ag-
onists (Hubbard et al., 2013; Milne et al., 2007).
We considered the possibility that helical motifs A and Bmight
interact with each other either in trans or within the native fold of
the NTERM domain (Figure 1A). The HA-tagged motif A peptide
was co-expressed with a series of Myc-tagged, N-terminally
truncated SIRT1 proteins and then immunoprecipitated with
an anti-HA antibody. Motif A efficiently co-immunoprecipitated
Myc-tagged SIRT1, SIRT1(D52), and SIRT1(D108) proteins,
and exhibited a weak interaction with SIRT1(D163) (Figure 2D).
However, the motif A peptide failed to interact with the
SIRT1(D221) protein lacking motif B (Figure 2D). The motif B
peptide (k) bound nonspecifically to the beads and could not
be tested for interactions by itself, although expression of
this peptide consistently decreased acetylation levels of NF-kB
(Figure 2B).
It was reported that recombinant SIRT1 dimerizes, and that
dimerization is abolished by the phosphomimetic mutation
Thr522Glu (Guo et al., 2012). However, we and others have
examined the oligomeric state of recombinant SIRT1 protein
purified from E. coli and find no evidence of dimer formation
(Lakshminarasimhan et al., 2013b; Figure S3). Sedimentation
equilibrium experiments conducted over a range of SIRT1 con-
centrations (5–50 mM) and g-forces indicated that recombinant
SIRT1 is monomeric with a buoyant mass of 90 kDa, consistent
with the calculated mass of 86 kDa (Figure S3A). The amino acid
sequence of the NTERM domain is predicted to be disordered
(Dunker et al., 2008; He et al., 2009), and the recombinant
SIRT1 protein has an anomalously small sedimentation coeffi-
cient (3.82S) and a large frictional coefficient that are indicative
of an elongated conformation (Figure S3C; Lakshminarasimhan
et al., 2013b). Consistent with the previous report (Guo et al.,
2012), dynamic light scattering shows an anomalously large Mr
value for SIRT1 (173 kDa, versus a calculated mass of 86 kDa)
(Figure S3B). In contrast, a truncated SIRT1(D221) protein
lacking the NTERM domain has an apparent mass (Mr =
73 kDa) in agreement with the expected value for a compact
globular protein. Thus, the unusually large hydrodynamic radius
of SIRT1 is a property of the NTERM domain, which may be
intrinsically disordered. The NTERM region also shows high
rates of hydrogen-deuterium exchange, a further indication of
an unfolded or loosely structured domain (Hubbard et al.,
2013). Disorder is frequently associated with protein interaction1668 Cell Reports 10, 1665–1673, March 17, 2015 ª2015 The Authorsites (Dunker et al., 2008), and correspondingly, the NTERM
domain contributes to interactions with substrates for deacetyla-
tion and with protein and small molecule activators of SIRT1 ac-
tivity (Kim et al., 2007b; Milne et al., 2007; Sinclair and Guarente,
2014).
Overexpression of the NTERM constructs allows the detection
of interactions in trans between motifs A and B (Figures 2B and
S2A) and the self-association of NTERM domains (Figure S2B).
Co-immunoprecipitation of NTERM domains may require an
elevated protein concentration, posttranslational modifications,
and/or partner proteins that are absent from in vitro studies of re-
combinant SIRT1 protein. The results with purified, recombinant
SIRT1 protein do not support a dimerization model. Instead, mo-
tifs A and B may pack together to stabilize the native fold of
SIRT1 monomers (Figure 1A).
The NTERM Domain Promotes the Interaction of SIRT1
with Substrates
NTERMoverexpression causes a decrease in levels of acetyl-p65
NF-kB (Figure 1B) that is suggestive of enhanced SIRT1 activity,
perhaps by promoting enzyme-substrate interactions. To ex-
amine this hypothesis, endogenous SIRT1 was pulled down
from extracts of HEK293 cells overexpressing the deacetylation
substrate NF-kB p65 that were co-transfected with increasing
amounts of NTERM. SIRT1was immunoprecipitatedwith an anti-
bodydirectedat itsC terminus, and the resultingprecipitates con-
tained a ternary complex of SIRT1, p65, andNTERM. The amount
of p65 in the complex increased concurrently with increased
expression of NTERM (Figure 3A), suggesting that the NTERM
domain does indeed promote the association of SIRT1 with the
NF-kB p65 substrate. Reciprocal pull-downs confirmed the for-
mation of a ternary p65/SIRT1/NTERM complex using antibodies
directed at NTERM (Figure 3B) or p65 (not shown).
To further probe the components of the SIRT1/NTERM/p65
complex, we attempted to measure the amounts of acetylated
and deacetylated p65 in the complex. To our surprise, p65 in
the complex was completely deacetylated, suggesting that,
once recruited into the complex, p65 is efficiently deacetylated
and remains complexed to SIRT1 (Figure 3C). Consistent with
these findings, the comparison of the deacetylation activities of
full-length SIRT1 and SIRT1(D221) on an in vitro acetylated p65
(1–325) substrate showed that the N-terminal domain of SIRT1
significantly enhances the rate of NF-kB p65 deacetylation
in vitro (Figure 3D). Because both SIRT1 and SIRT1(D221) exhibit
similar kinetics toward a peptide substrate (not shown), these
results suggest that the NTERM domain likely enhances deace-
tylation activity toward protein substrates by promoting the
enzyme-substrate interaction.
The co-immunoprecipitation of the NTERM domain with the
enzyme-substrate complex is consistent with a direct effect of
NTERM on the substrate-binding activity of SIRT1. Alternatively,
the overexpressed NTERM domain could sequester a negative
regulator of SIRT1, such as the DBC1 protein, a competitive in-
hibitor of SIRT1 substrate-binding activity (Kim et al., 2008;
Zhao et al., 2008). In this scenario, a physical interaction be-
tween NTERM and DBC1 would antagonize DBC1-dependent
inhibition of SIRT1. We examined this hypothesis by co-express-
ing FLAG-tagged DBC1 and HA-tagged NTERM proteins ins
Figure 3. NTERM Enhances the Interaction
of SIRT1 with Its Substrate NF-kB p65
(A) Overexpression of NTERM in HEK293 cells
increases the interaction between endogenous
SIRT1 and its substrate, the p65 subunit of NF-kB.
HEK293 cells were co-transfected with p65
together with increasing concentrations of NTERM
(1, 2, or 4 mg plasmid DNA), and endogenous
SIRT1 protein was immunoprecipitated with an
antibody directed at a C-terminal epitope of hu-
man SIRT1. Increasing expression of HA-NTERM
resulted in a greater association of SIRT1 with p65
and with NTERM in a ternary complex (right).
(B) In a reciprocal pull-down experiment, HA-
NTERM was co-immunoprecipitated in a complex
with SIRT1 and p65.
(C) p65 in the complex with SIRT1 and NTERM
is fully deacetylated at Lys310. Immunoprecipita-
tion was performed as in (A) and blots were
probed with antibodies for total p65 and acetyl-
(Lys310)-p65.
(D) In vitro deacetylation of the purified p65 protein
is enhanced by the presence of the NTERM
domain. Deacetylation of lysine 310 was moni-
tored bywestern blotting for p65 acetylated in vitro
by pretreatment with the histone acetyltransferase
domain of p300. The p65 protein substrate is de-
acetylated at a significantly faster rate by SIRT1
than by SIRT1(D221) lacking the NTERM domain.
The means and SEs of three experiments are
shown, after normalization to the activity of SIRT1.HEK293 cells and pulling down the NTERM domain with an anti-
HA antibody. DBC1 was efficiently co-immunoprecipitated by
NTERM (Figure S4A), and the reciprocal immunoprecipitation
confirmed this interaction (Figure S4B). The DBC1 binding site
previously was localized to the catalytic core of SIRT1 (Kim
et al., 2008; Zhao et al., 2008). However, protein constructs
described as the catalytic core in these studies included all
(Kim et al., 2008) or part of (Zhao et al., 2008) the region we
have defined as motif B of the NTERM domain. The NTERM
domain of SIRT1 is sufficient for interaction with DBC1 (Fig-
ure S4B), and a SIRT1 deletion mutant lacking the NTERM
domain does not interact with DBC1 (Figure S4C). Constructs
that include motif B (residues 163–221; Figure 1A) also bind
to DBC1 (Figure S4D), whereas the motif A peptide (residues
1–52) does not bind (Figure S4D).
Although overexpression of DBC1 caused a modest increase
in acetyl-p53 levels, this effect was overcome by low-level
expression of the NTERM domain (Figure S4E). Increasing the
level of DBC1 expression did not antagonize the effect of NTERM
on acetyl-p53 levels (Figure S4E). The interaction of DBC1 with
SIRT1 is regulated by phosphorylation of both proteins (Nin
et al., 2012; Yuan et al., 2012), and DBC1may not be the primary
determinant of SIRT1 activity in HepG2 cells under our experi-
mental conditions. Other investigators have similarly reported
that DBC1 does not consistently function as an inhibitor of
SIRT1 activity in every cell line tested (Bae et al., 2012). The
co-immunoprecipitation of NTERM and SIRT1 (Figure 2A) is
consistent with a direct effect of the NTERM domain on the sub-
strate-binding and enzymatic activities of SIRT1.CellThe Motif A Peptide Improves Glucose Metabolism
in Mice
To examine the metabolic effects of NTERM expression in vivo,
we constructed recombinant adenoviruses expressing SIRT1
and the motif A peptide (residues 1–52). Despite repeated at-
tempts, we were unable to recover virus from an expression
construct encoding the NTERM domain. Male C57BL/6 mice at
approximately 2 months of age were infected with the other
two recombinant viruses by tail vein injection, and overexpres-
sion of SIRT1 and the motif A peptide were confirmed 4 days
post-infection by western blot analysis (Figure 4A). In agreement
with previous reports (Rodgers and Puigserver, 2007; Rodgers
et al., 2005), animals overexpressing SIRT1 had lower fasting
glucose levels (Figure 4B) and significantly improved glucose
tolerance measured by an intraperitoneal glucose tolerance
test (IPGTT) (Figure 4C). Remarkably, overexpression of the
motif A peptide had a similar effect of reducing fasting glucose
levels and improving glucose tolerance in comparison to control
animals overexpressing the GFP (Figures 4B and 4C). Insulin
levels measured during the IPGTTwere similar for the control an-
imals and those expressing SIRT1 or the motif A peptide (Fig-
ure 4D). These findings suggest that expression of the motif A
peptide likely improves insulin sensitivity, an effect similar to
overexpressing enzymatically active SIRT1 (Erion et al., 2009;
Rodgers and Puigserver, 2007). Enhanced SIRT1 activity in the
liver of the transduced animals also was evidenced by increased
expression of stearoyl-CoA desaturase 1 (Scd1) in mice overex-
pressing the motif A peptide (Figure 4E), an effect comparable to
overexpression of SIRT1 (Ramsey et al., 2008).Reports 10, 1665–1673, March 17, 2015 ª2015 The Authors 1669
Figure 4. Expression of NTERM Improves
Glucose Metabolism In Vivo
(A) Representative immunoblot of Flag-tagged
SIRT1 and Flag-tagged motif A (residues 1–52)
expression from three mouse livers in each group.
(B) Fasted glucose levels were measured in mice
4 days post-infection with adenoviruses express-
ing GFP, SIRT1, or NTERM motif A and after
fasting animals for 16 hr. Expression of SIRT1 or
the motif A peptide caused a significant reduction
in fasting glucose.
(C) An IPGTT was performed as previously
described (Ramsey et al., 2008) in mice 4 days
post-infection with the adenoviruses (left) and the
areas under the curve (AUCs) were calculated for
each group (right). The AUC values are presented
as the mean and SE of each group.
(D) Plasma insulin levels measured during the
IPGTT were not significantly different for the three
groups of animals, suggesting that the motif A
peptide increases insulin sensitivity in mice but
does not alter insulin secretion.
(E)Mouse livermRNAwas isolated and expression
levels of Scd1 were evaluated by qRT-PCR.
The means and SEs are shown (n = 9–11). The
three groups were analyzed by one-way ANOVA
and Fisher’s PLSD post hoc test; *p < 0.05, **p <
0.01, ***p < 0.001.DISCUSSION
SIRT1 broadly regulates cellular metabolism, growth, and re-
sponses to stress by deacetylating transcription factors and his-
tones, yet we have limited knowledge of mechanisms governing
substrate selection by SIRT1 and the control of deacetylation ac-
tivity (Haigis and Sinclair, 2010; Satoh et al., 2011; Sinclair and
Guarente, 2014). Acetyl-lysine-containing peptides are promis-
cuously deacetylated in vitro by SIRT1with little sequence selec-
tivity (Blander et al., 2005; Lakshminarasimhan et al., 2013a),
suggesting that additional binding interactions with protein
substrates contribute to the biological specificity of deacetyla-
tion in a cellular context. Here we identify protein interactions
mediated by the N-terminal domain of SIRT1 that increase
SIRT1-dependent activities, decreasing acetylation of the NF-
kB p65 and p53 proteins and increasing expression of Pepck
(Figure 1E) and Scd1 (Figure 4E). The physical interaction of
NTERM with SIRT1 promotes the recruitment of a protein sub-
strate NF-kB p65 into the enzyme-substrate complex, suggest-
ing a mechanism for enhancing deacetylation of this protein.1670 Cell Reports 10, 1665–1673, March 17, 2015 ª2015 The AuthorsAdditionally, the NTERM domain inter-
acts with DBC1, a negative regulator of
SIRT1 activity (Kang et al., 2011; Kim
et al., 2008; Zhao et al., 2008). The bind-
ing of DBC1 to the NTERM domain
may additionally contribute to enhanced
SIRT1 deacetylase activity.
Several models can be envisioned for
the regulation of SIRT1 enzymatic activity
by the NTERM domain. The self-associa-
tion of overexpressed NTERM domainsthrough an interaction of motifs A and B is consistent with
SIRT1 dimerization (Guo et al., 2012), although recombinant
SIRT1 proteins purified from E. coli or Sf9 insect cells are mono-
meric (Lakshminarasimhan et al., 2013b). SIRT1 oligomerization
may require additional posttranslational modifications or partner
proteins that assemble into amultiprotein complex. Alternatively,
the NTERMdomainmay function in cis to enhance the substrate-
binding and deacetylase activities of the SIRT1 catalytic core.
The interacting motifs A and B could pack together in the folded
conformation of the NTERM domain, an interaction that could be
stabilized in complex with a SIRT1 substrate. In addition, sites of
phosphorylation within activating motifs A and B (Back et al.,
2011; Kang et al., 2009; Nasrin et al., 2009) may affect the
conformation of NTERM or its interactions with protein partners.
It is also notable that motif B corresponds to a region of SIRT1
that is essential for activation of deacetylase activity by small
molecules (Hubbard et al., 2013; Milne et al., 2007; Sinclair and
Guarente, 2014).
Viral transduction of a 52-residue peptide corresponding to
motif A of the NTERM domain improved glucose metabolism in
mice, coincident with overexpression of the peptide in the liver.
The precise mechanism for these in vivo effects is still being
investigated but may be related to the downregulation of NF-
kB signaling by enhancing SIRT1 activity. So far, we have not
been able to reconstitute the activation event of SIRT1 enzymatic
activity in vitro upon addition of the purified recombinant NTERM
domain, or the interaction of NTERMwith the purified p65Rel ho-
mology domain (residues 1–325). These results are consistent
with the proposal that SIRT1 may be a part of a larger complex
in which additional factors physically interact with NTERM,
SIRT1, and substrate proteins in cells.
The active regulator of SIRT1 (AROS) enhances the SIRT1-
dependent deacetylation of p53 by binding to the N-terminal
domain of SIRT1 (Kim et al., 2007b) in a region (residues 114–
217) that includes the activating motif B. It has been suggested
that AROS may induce a conformational change of SIRT1 to
stimulate deacetylase activity. One could envision positive regu-
lators of SIRT1 activity stabilizing the interaction of motifs A and
B to promote interactions with substrates, whereas DBC1 and
negative regulators might stabilize an inactive conformation of
the NTERM domain. To address such possibilities, it will be
important to identify additional regulators of SIRT1 activity that
may affect the conformation and/or the function of the NTERM
domain. Structural studies of SIRT1 in complex with those regu-
latory proteins also will be important for understanding the
mechanisms of regulating its enzymatic activity by proteins
and by small molecules.
In conclusion, we have identified functional interactions of the
SIRT1 NTERM domain and, specifically, the activating motifs A
and B that enhance SIRT1-dependent activities in cells and in
mice. Our results provide new insights into possible interventions
that modulate SIRT1 activity through the binding interactions of
the NTERM domain.EXPERIMENTAL PROCEDURES
Acetylation Levels of SIRT1 Substrates
HepG2 cells were transfected with expression plasmids constructed from
pCMV-HA and pCMV-Myc vectors (Clontech Laboratories) and encoding
NF-kB p65 (Chen et al., 2001) or p53, and SIRT1, NTERM, SIRT1(D221),
or SIRT1(509–737) using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. Twenty-four hours later, the media were re-
placed with DMEM containing deacetylase inhibitors (10 mM trichostatin
A, 10 mM nicotinamide) and cells were incubated overnight. Cells were
treated for 48 hr with the SIRT1 inhibitor EX-527 at a concentration of
10 or 25 mM. For immunoprecipitation, cells were harvested in cold PBS
including deacetylase inhibitors, pelleted at 1,000 3 g, and lysed in immu-
noprecipitate (IP) buffer as previously described (Grimm et al., 2011). After
normalizing the protein concentrations, the samples were analyzed by
SDS-PAGE and western blotting as described below. The band intensities
were quantitated using Image J (NIH) and plotted as the normalized mean
and SE.
Co-immunoprecipitation and Western Blotting
Cells were transfected with the following constructs as indicated:
Myc-SIRT1, HA-SIRT1(1–221), HA-SIRT1(1–52), Myc-SIRT1(D221), Myc-
SIRT1(509–737), Myc-SIRT1(D52), Myc-SIRT1(D108), Myc-SIRT1(D163),
Myc-SIRT1(1–221), or DBC1 using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s protocol. Immunoprecipitation was performed as
previously described (Grimm et al., 2011). In brief, cell extracts were pre-
cleared with a 50% slurry of protein A agarose beads (Millipore) in IP bufferCellfor 2 hr at 4C. For Flag, HA, or Myc IP, 30 ml anti-Flag-conjugated agarose
beads (Sigma), anti-HA-conjugated agarose beads (Sigma), or anti-Myc-
conjugated agarose beads (Clontech) were added, and the samples were
rocked overnight at 4C. Endogenous SIRT1 was immunoprecipitated by
incubating cell extracts overnight with anti-SIRT1 (Santa Cruz Biotechnology
B-7, C-terminal antibody) followed by protein G beads (Sigma) for 2 to 3 hr at
4C. Western blotting was performed as previously described (Revollo et al.,
2004). To visualize SIRT1 peptides, the membranes were incubated
with 10% glutaraldehyde (Sigma) in PBS for 30 min immediately before
blocking. Primary antibodies included a-SIRT1 (1:10,000, Upstate Biotech-
nology), a-SIRT1 (1:5,000, Sigma AS-16), a-hSIRT1 (1:1,000, Abcam
19A7AB4), a-hSIRT1 (1:1,000, Santa Cruz B-7), a-Myc (1:500, Clontech),
a-NF-kB (1:1,000, Santa Cruz), a-tubulin (1:1,000, Santa Cruz), a-acetyl-
NF-kB (1:1,000, Cell Signaling Technology), a-HA (1:1,000, Covance),
a-Flag (1:1,000, Sigma), and a-acetyl-p53 Lys-379 (1:1,000, Cell Signaling
Technology). Secondary antibodies included the HRP-conjugated a-rabbit
IgG or a-mouse IgG (1:10,000, GE Healthcare) and a-rabbit IgG (1:1,000,
Cell Signaling Technology).
Animal Experimentation
All animal studies were approved by the Washington University Animal
Studies Committee and performed in accordance with NIH guidelines. Re-
combinant adenoviruses expressing GFP, SIRT1, or motif A (residues 1–52)
proteins were prepared following the manufacturer’s protocol (Invitrogen
AddEasy) and used to infect 8- to 10-week-old male C57BL/6J mice (Ta-
conic Laboratories) by tail vein injection of 5 3 109 virus particles. After
4 days, IPGTT was performed as previously described (Ramsey et al.,
2008). Significant differences between groups of animals were determined
using a one-way ANOVA with the Fisher’s PLSD test. For the detection of
SIRT1 and the motif A peptide, mice were sacrificed by carbon dioxide
asphyxiation after IPGTT experiments. Livers were immediately collected,
minced, and flash frozen in liquid nitrogen. Liver samples were homoge-
nized in 23 Laemmli sample buffer and boiled for 5 min. Samples were
then centrifuged to remove debris and protein concentration was measured
by the Bradford assay.
Analytical Ultracentrifugation
Experiments were performed at 25C using a Beckman Instruments Optima
XL-A analytical ultracentrifuge. For sedimentation velocity (SV) experi-
ments, sample cells were loaded with 380 ml SIRT1 or 400 ml appropriate
reference buffer and then centrifuged at 40,000 rpm. Data were collected
in continuous mode at a wavelength of 280 nm and fitted to a continuous
sedimentation coefficient [c(s)] distribution model using the program
SEDFIT (NIH). The sedimentation coefficient for SIRT1 was determined at
a protein concentration of 40 mM in a buffer containing 50 mM NaCl,
50 mM HEPES (pH 8.0), 2 mM MgCl2, 1 mM TCEP, and 0.1 mM EDTA.
Sedimentation coefficients were determined in the presence of one or
both substrates, NAD+ (1 mM) and/or a thio-acetyl lysine peptide
(400 mM) corresponding to lysine 382 of the p53 protein, by monitoring
absorbance at 295 nm.
For sedimentation equilibrium (SE) experiments, an Epon charcoal-filled six-
sector centerpiece was used allowing three concentrations to be run simulta-
neously (5, 10, and 50 mM). Cells were loaded with 120 ml protein sample and
130 ml appropriate reference buffer. Optical absorbance values were moni-
tored at 280 nm and runs were performed at speeds of 12,000, 15,000,
18,000, and 22,000 rpm until equilibrium was achieved (24 hr determined
from overlap of scans at 4-hr separation). Sedimentation equilibrium data
were processed and analyzed using SEDFIT/SEDPHAT (Lebowitz et al.,
2002), and values for partial specific volume and solvent density were calcu-
lated using SEDNTERP.
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